Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTB AIEOP 012 study in newly diagnosed retinoblastoma
2011-006109-85Phase 2Terminated
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Mar 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide phosphate, vincristine and ifosfamide in retinoblastoma (Rb), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: Ocular event-free survival at 12 months from diagnosis. Started Mar 2012; status: terminated.
02
Drugs
carboplatinetoposide phosphatevincristineifosfamide
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2011-006109-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006109-85.